Ivabradine for the treatment of chronic heart failure

References

• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–1146.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Kaul P, Bakal JA, et al. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail. 2011;13:142–147.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–821.
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Jones MI, Allan TF, et al. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J. 2000;21:1877–1887.
   PubMed Web of Science ®Google Scholar
• Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30:478–486.
   PubMed Web of Science ®Google Scholar
• Cohen-Solal A. [Management of heart failure by general practitioners in France. Results of the study IMPROVEMENT of heart failure (IMPROVEMENT-HF)]. Arch Mal Coeur Vaiss. 2002;95 Spec 4:11–15.
   PubMedGoogle Scholar
• De Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007;9:1205–1211.
   PubMed Web of Science ®Google Scholar
• Mehta PA, McDonagh S, Poole-Wilson PA, et al. Heart failure in a district general hospital: are target doses of beta-blockers realistic? Qjm. 2004;97:133–139.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347–356.
   PubMed Web of Science ®Google Scholar
• Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart. 2000;84:615–619.
   PubMed Web of Science ®Google Scholar
• Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail. 2006;8:302–307.
   PubMed Web of Science ®Google Scholar
• Gupta R, Tang WH, Young JB. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J. 2004;147:79–83.
   PubMed Web of Science ®Google Scholar
• Abrahamyan L, Trubiani G, Witteman W, et al. Insights into the contemporary management of heart failure in specialized multidisciplinary ambulatory clinics. Can J Cardiol. 2013;29:1062–1068.
   PubMed Web of Science ®Google Scholar
• Allaert FA, Mosnier M. Analysis of ambulatory heart failure management and its incidence on one-year survival. Ann Can Cardiovasc Soc Heart Fail Angeiol (Paris). 2008;57:22–28.
   PubMedGoogle Scholar
• Gonzalez-Juanatey JR, Alegria Ezquerra E, Bertomeu Martinez V, et al. [Heart failure in outpatients: comorbidities and management by different specialists. The EPISERVE Study]. Rev Esp Cardiol. 2008;61:611–619.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076–1084.
   PubMed Web of Science ®Google Scholar
• Fruhwald FM, Rehak P, Maier R, et al. Austrian survey of treating heart failure–AUSTRIA. Eur J Heart Fail. 2004;6:947–952.
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Shankar A, McManus RJ, et al. Evaluation of the management of heart failure in primary care. Fam Pract. 2009;26:145–153.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–869.
   PubMed Web of Science ®Google Scholar
• Howlett JG, Chan M, Ezekowitz JA, et al. The Canadian Cardiovascular Society heart failure companion: bridging guidelines to your practice. Can J Cardiol. 2016;32:296–310.
   PubMed Web of Science ®Google Scholar
• Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–974.
   PubMed Web of Science ®Google Scholar
• Custodis F, Schirmer SH, Baumhakel M, et al. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010;56:1973–1983.
   PubMed Web of Science ®Google Scholar
• Reil JC, Reil GH, Bohm M. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc Med. 2009;19:152–157.
   PubMed Web of Science ®Google Scholar
• White M, Rouleau JL, Ruddy TD, et al. Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure. J Am Coll Cardiol. 1991;18:1631–1637.
   PubMed Web of Science ®Google Scholar
• McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–794.
   PubMed Web of Science ®Google Scholar
• Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865–869.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355.
   PubMed Web of Science ®Google Scholar
• Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF trial. Clin Cardiol. 1999;22 Suppl 5:V30–V35.
   PubMed Web of Science ®Google Scholar
• Ertle G. [CIBIS-II Study. Bisoprolol in patients with chronic heart failure]. Internist (Berl). 2000;41:1270–1272.
   PubMedGoogle Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390.
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–2199.
   PubMed Web of Science ®Google Scholar
• Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26:2259–2268.
   PubMed Web of Science ®Google Scholar
• Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–1433.
   PubMed Web of Science ®Google Scholar
• Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. 2012;14:737–747.
   PubMed Web of Science ®Google Scholar
• Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437–459.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT study. J Am Coll Cardiol. 2012;59:1938–1945.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170:182–188.
   PubMed Web of Science ®Google Scholar
• DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106:434–446.
   PubMed Web of Science ®Google Scholar
• DiFrancesco D, Borer JS. The funny current: cellular basis for the control of heart rate. Drugs. 2007;67 Suppl 2:15–24.
   PubMed Web of Science ®Google Scholar
• Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676–H682.
   PubMed Web of Science ®Google Scholar
• Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589–1601.
   PubMed Web of Science ®Google Scholar
• Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301–2309.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9:95–108.
   PubMed Web of Science ®Google Scholar
• O’Meara E, Thibodeau-Jarry N, Ducharme A, et al. The epidemic of heart failure: a lucid approach to stemming the rising tide. Can J Cardiol. 2014;30:S442–S454.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–1277.
   PubMed Web of Science ®Google Scholar
• Toischer K, Lehnart SE, Tenderich G, et al. K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum. Basic Res Cardiol. 2010;105:279–287.
   PubMed Web of Science ®Google Scholar
• Kaupp UB, Seifert R. Molecular diversity of pacemaker ion channels. Annu Rev Physiol. 2001;63:235–257.
   PubMed Web of Science ®Google Scholar
• Biel M, Schneider A, Wahl C. Cardiac HCN channels: structure, function, and modulation. Trends Cardiovasc Med. 2002;12:206–212.
   PubMed Web of Science ®Google Scholar
• Thollon C, Bedut S, Villeneuve N, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150:37–46.
   PubMed Web of Science ®Google Scholar
• Bucchi A, Baruscotti M, Nardini M, et al. Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS One. 2013;8:e53132.
   PubMed Web of Science ®Google Scholar
• Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051–1057.
   PubMed Web of Science ®Google Scholar
• Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol. 1997;339:43–51.
   PubMed Web of Science ®Google Scholar
• Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37–42.
   PubMed Web of Science ®Google Scholar
• Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1–13.
   PubMed Web of Science ®Google Scholar
• Bucchi A, Tognati A, Milanesi R, et al. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572:335–346.
   PubMed Web of Science ®Google Scholar
• Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–666.
   PubMed Web of Science ®Google Scholar
• Procoralan-summary of product characteristics. Neuilly sur Seine: Les laboratoires Servier [Internet]. 2005 [cited 2016 Mar 24]. Available from: http://ec.europa.eu/health/documents/communityregister/2005/2005102510136/anx_10136_en.pdf.
   Google Scholar
• Gardiner SM, Kemp PA, March JE, et al. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol. 1995;115:579–586.
   PubMed Web of Science ®Google Scholar
• Lucats L, Ghaleh B, Colin P, et al. Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening. Br J Pharmacol. 2007;150:335–341.
   PubMed Web of Science ®Google Scholar
• Milliez P, Messaoudi S, Nehme J, et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol. 2009;296:H435–H441.
   PubMed Web of Science ®Google Scholar
• Heusch G, Skyschally A, Gres P, et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008;29:2265–2275.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4:83–89.
   PubMedGoogle Scholar
• Manz M, Reuter M, Lauck G, et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–155.
   PubMed Web of Science ®Google Scholar
• De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550–555.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816.
   PubMed Web of Science ®Google Scholar
• Ceconi C, Freedman SB, Tardif JC, et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;146:408–414.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
   PubMed Web of Science ®Google Scholar
• Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886–894.
   PubMed Web of Science ®Google Scholar
• Borer JS, Bohm M, Ford I, et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT Study). Am J Cardiol. 2014;113:497–503.
   PubMed Web of Science ®Google Scholar
• Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33:2813–2820.
   PubMed Web of Science ®Google Scholar
• Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–2515.
   PubMed Web of Science ®Google Scholar
• Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62:1977–1985.
   PubMed Web of Science ®Google Scholar
• Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395–2404.
   PubMed Web of Science ®Google Scholar
• Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119:2516–2525.
   PubMed Web of Science ®Google Scholar
• Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34:2263–2270.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151:218–224.
   PubMed Web of Science ®Google Scholar
• Kosmala W, Holland DJ, Rojek A, et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–1338.
   PubMed Web of Science ®Google Scholar
• Simantirakis EN, Nakou ES, Kallergis EM, et al. Long-term effect of If-channel inhibition on diastolic function and exercise capacity in heart failure patients with preserved ejection fraction. Int J Cardiol. 2015;187:9–11.
   PubMed Web of Science ®Google Scholar
• Pal N, Sivaswamy N, Mahmod M, et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015;132:1719–1725.
   PubMed Web of Science ®Google Scholar
• Roubille F, Tardif JC. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation. 2013;127:1986–1996.
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. I f inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31:95–107.
   PubMed Web of Science ®Google Scholar
• Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol. 2011;107:805–811.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
   Google Scholar
• Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269–279.
   PubMed Web of Science ®Google Scholar
• Gandhi PU, Testani JM, Ahmad T. The current and potential clinical relevance of heart failure biomarkers. Curr Heart Fail Rep. 2015;12:318–327.
   PubMedGoogle Scholar
• O’Meara E, Mielniczuk LM, Wells GA, et al. Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial. Trials. 2013;14:218.
   PubMed Web of Science ®Google Scholar